Endo Health Solutions (NASDAQ: ENDP )
has not been shy about using M&A to rebuild its growth prospects
in the wake of losing patent coverage on Lidoderm and Opana ER. While
prior management didn't do well with its M&A, new management has
already made some smart (albeit not necessarily cheap) deals for Paladin
Labs and Boca Pharmaceutical. Now management is going for for a
different sort of deal -- the acquisition of NuPathe (NASDAQ: PATH )
is hardly a slam dunk value-adding deal, but the upfront consideration
of $105 million excluding deal costs is not a terribly high price to
pay for taking a chance.
Please follow this link:
A Pain Specialist Buys a Technology Call Option
No comments:
Post a Comment